| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Cereblon
CRBN (cereblon), an E3 ubiquitin ligase. |
|---|---|
| ln Vitro |
As a cereblon-binding ligand-linker conjugate, Lenalidomide-C5-amido-Boc itself has no intrinsic biological activity; its function is to bind to cereblon and recruit the E3 ubiquitin ligase complex. The Boc-protected amine provides a protected handle for conjugation. After deprotection under acidic conditions, the resulting free primary amine can be coupled to a carboxylic acid-containing target protein ligand (or a linker attached to such a ligand) via amide bond formation using standard coupling reagents (e.g., EDC, HATU). The resulting PROTAC can ubiquitinate and degrade the target protein via the proteasome. The C5 alkyl spacer provides moderate length and flexibility, which can be optimized for specific target proteins.
|
| ln Vivo |
No specific in vivo activity has been reported for this conjugate alone; its in vivo degradation activity is observed only when conjugated to a target protein ligand to form a complete PROTAC molecule. The in vivo efficacy of such a PROTAC is typically evaluated in animal models of target-driven diseases.
|
| Enzyme Assay |
N/A; this compound is not assessed in isolated enzyme/receptor binding assays. As a synthetic intermediate, its quality is confirmed by analytical methods such as HPLC and NMR, with a standard purity of ≥95-98%. Its binding affinity to cereblon is validated as part of a complete PROTAC construct using biophysical methods such as surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC). The Boc protecting group can be characterized by NMR spectroscopy.
|
| Cell Assay |
N/A; this conjugate is not tested alone in cell-based assays but is used as a building block for constructing PROTACs. In a typical conjugation workflow, the Boc group is first removed using TFA to reveal a primary amine. The free amine is then conjugated to a target protein ligand (or a linker attached to such a ligand) using EDC/NHS or other coupling reagents. The resulting PROTAC is purified and then tested in target-expressing cells for degradation activity by Western blotting to determine the DC50 (half-maximal degradation concentration).
|
| Animal Protocol |
N/A; no animal studies are performed with the ligand-linker conjugate alone. For in vivo studies of a complete PROTAC, the molecule is formulated in a suitable vehicle (e.g., 10% DMSO, 40% PEG300, 5% Tween-80, 45% saline) and administered to animal models via intraperitoneal (IP) or intravenous (IV) injection. Target degradation in tissues and tumor growth inhibition are monitored. The C5 alkyl linker may be optimized for specific target-E3 ligase pairs.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of 429.51, a molecular formula of C23H31N3O5, and a purity of ≥95-98% (HPLC). It appears as a solid powder. For storage, it should be kept as a powder at -20degC, sealed, away from moisture and light. In a solvent, it can be stored at -80degC for 6 months or at -20degC for 1 month. It is soluble in DMSO. The IUPAC name is tert-butyl (5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)pentyl)carbamate.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not for human therapeutic or clinical applications. Standard chemical safety precautions should be followed during handling. The product has not been fully validated for medical applications. It is a PROTAC building block and is not an approved therapeutic drug. Lenalidomide is an immunomodulatory drug (IMiD) clinically used for multiple myeloma and myelodysplastic syndromes; this derivative is for research purposes only.
|
| References |
|
| Additional Infomation |
The combination of a Lenalidomide-based cereblon ligand and a C5 alkyl spacer with a Boc-protected amine provides a versatile building block for constructing cereblon-recruiting PROTACs. The C5 alkyl linker (five-carbon chain) provides a medium-length, flexible spacer that can be optimized for specific target-E3 ligase pairs. The amide bond within the linker enhances structural rigidity and may improve metabolic stability compared to purely alkyl-based linkers. This conjugate is valuable for PROTAC R&D and for studying cereblon-mediated protein degradation.
|
| Molecular Formula |
C23H31N3O5
|
|---|---|
| Molecular Weight |
429.51
|
| Exact Mass |
429.226
|
| CAS # |
2138441-25-3
|
| PubChem CID |
145926837
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
31
|
| Complexity |
702
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)OC(=O)NCCCCCC1=C2CN(C(=O)C2=CC=C1)C3CCC(=O)NC3=O
|
| InChi Key |
HEDNUGMKVBGPTI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H31N3O5/c1-23(2,3)31-22(30)24-13-6-4-5-8-15-9-7-10-16-17(15)14-26(21(16)29)18-11-12-19(27)25-20(18)28/h7,9-10,18H,4-6,8,11-14H2,1-3H3,(H,24,30)(H,25,27,28)
|
| Chemical Name |
tert-butyl N-[5-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]pentyl]carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~90 mg/mL (~209.54 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.25 mg/mL (5.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3282 mL | 11.6412 mL | 23.2823 mL | |
| 5 mM | 0.4656 mL | 2.3282 mL | 4.6565 mL | |
| 10 mM | 0.2328 mL | 1.1641 mL | 2.3282 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
